Norethindrone Acetate in the Medical Management of Adenomyosis [PDF]
The role of norethindrone acetate (NA) in the management of adenomyosis was evaluated with a retrospective chart review of 28 premenopausal women between 27–49 years of age presenting with moderate to severe pelvic pain and bleeding.
Siddhi Mankame+4 more
doaj +4 more sources
A Novel Intrauterine Device for the Spatio-Temporal Release of Norethindrone Acetate as a Counter-Estrogenic Intervention in the Genitourinary Syndrome of Menopause [PDF]
The genitourinary syndrome of menopause (GSM) is a widely occurring condition affecting millions of women worldwide. The current treatment of GSM involves the use of orally or vaginally administered estrogens, often with the risk of endometrial ...
Ahmed Abdelgader+3 more
doaj +4 more sources
Unilateral Erythema Nodosum following Norethindrone Acetate, Ethinyl Estradiol, and Ferrous Fumarate Combination Therapy [PDF]
Erythema nodosum is a septal panniculitis that typically presents as symmetric, tender nodules on the anterior aspects of bilateral lower extremities.
Michelle S. Min+2 more
doaj +4 more sources
Oral GnRH Antagonists in Combination with Estradiol and Norethindrone Acetate for Pain Relief Associated with Endometriosis: A Review of Evidence of a Novel Class of Hormonal Agents [PDF]
Essam R Othman,1,2 Ayman Al-Hendy,3 Radwa Mostafa,1 Cornelis B Lambalk,2 Velja Mijatovic2 1OB-GYN Department, Assiut University, Assiut, 71515, Egypt; 2Academic Endometriosis Center, Amsterdam University Medical Center, Vrije Universiteit Amsterdam ...
Othman ER+4 more
doaj +4 more sources
The effect of low-dose combined hormone therapy (oestradiol and norethindrone acetate) on serum C-reactive protein levels and life quality in natural menopause women [PDF]
Servin Gocer+3 more
doaj +4 more sources
Medical management of recurrent endometrioma with long-term norethindrone acetate [PDF]
Ozgul Muneyyirci-Delale1,2, Jenny Anopa1, Cassandra Charles1, Deepali Mathur1, Rudolph Parris1, Jed B Cutler2, Ghadir Salame1,2, Ovadia Abulafia1,21Department of Obstetrics and Gynecology, SUNY Downstate Medical Center, New York, NY, USA; 2Department of ...
Muneyyirci-Delale O+7 more
doaj +4 more sources
HT update: spotlight on estradiol/norethindrone acetate combination therapy [PDF]
Colleen L Casey, Christine A MurrayUniversity of Vermont, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Burlington, VT, USAAbstract: The goal of postmenopausal hormone therapy is to alleviate the ...
Colleen L Casey, Christine A Murray
doaj +4 more sources
Suppression of an accessory and cavitated uterine mass with norethindrone: a case report [PDF]
Objective: To describe conservative management for accessory and cavitated uterine mass (ACUM) with norethindrone acetate. The patient gave signed written, informed consent authorizing publication.
Hope Knochenhauer, M.D.+2 more
doaj +2 more sources
Bioequivalence of Elagolix/Estradiol/Norethindrone Acetate Fixed‐Dose Combination Product: Phase 1 Results in Healthy Pre‐ and Postmenopausal Women [PDF]
Abstract Fixed‐dose combination (FDC) therapies can enhance patient convenience and adherence to prescribed treatment regimens. Elagolix is a novel oral gonadotropin‐releasing hormone receptor antagonist approved for management of moderate to severe pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids ...
Mong‐Jen Chen+5 more
openalex +2 more sources
The effects of conventional doses of two synthetic contraceptive steroids on the concentration and rate of secretion of plasma triglycerides from the splanchnic region were investigated.
B M Wolfe, D M Grace
doaj +2 more sources